Home | Welcome to Contract Pharma   
Last Updated Thursday, September 18 2014
Print RSS Feed

Cytovance Manufactures ARMO’s Lead Candidate



Published June 23, 2014
Related Searches: Phase I contractpharma.com Development www.contractpharma.com
Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.
 
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
 
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase I dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On